Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Urinary Bladder Neoplasms 3Uterine Cervical Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

pembrolizumab 5padeliporfin 5Nivolumab 5fludarabine 4aldesleukin 4Ipilimumab 4Cyclophosphamide 4atezolizumab 3Sunitinib 3Specimen Handling 3Paclitaxel 3Mitomycin 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Drug Therapy 3Carboplatin 3Biopsy 3Abiraterone Acetate 3vedolizumab 2olaparib 2niraparib 2motexafin gadolinium 2enfortumab vedotin 2darolutamide 2cabozantinib 2anlotinib 2abiraterone 2Therapeutics 2Suspensions 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × ferumoxtran-10 × Clear all
NCT00147238 2012-08-07

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

M.D. Anderson Cancer Center

Phase NA Terminated
10 enrolled 3 charts
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡